PrimeGenX Therapeutics

Company Deals

PrimeGenX Therapeutics Files Hong Kong IPO for Pumecitinib Platform

Fineline Cube Feb 3, 2026

PrimeGenX Therapeutics Co., Ltd., a Beijing‑based immuno‑inflammation biotech founded in 2016, made an initial public...

Company Deals

Jumpcan Licenses PrimeGenX Pumecitinib Nasal Spray for Allergic Rhinitis

Fineline Cube Feb 3, 2026

Jumpcan Pharmaceutical (SHA: 600566) announced a partnership with PrimeGenX Therapeutics Co., Ltd. granting Jumpcan exclusive...

Company Deals

Insilico Medicine Doses First Patient in MEN2501 Phase I, Triggers $5M Menarini Milestone

Company Deals

PrimeGenX Therapeutics Files Hong Kong IPO for Pumecitinib Platform

Company Medical Device

Hengrui Resubmits Camrelizumab-Apatinib BLA for HCC to FDA

Company Deals

Jumpcan Licenses PrimeGenX Pumecitinib Nasal Spray for Allergic Rhinitis